NCT02314377View on ClinicalTrials.gov

Bevacizumab Therapy for Brain Arteriovenous Malformation

PHASE1CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

December 1, 2018

Study Completion Date

December 1, 2019

Conditions
Brain Arteriovenous Malformation
Interventions
DRUG

Bevacizumab

Bevacizumab dosing of 5mg/kg q 2 weeks for 12 weeks (2.5 mg/week).

Trial Locations (1)

94143

University of California San Francisco, San Francisco

All Listed Sponsors
lead

University of California, San Francisco

OTHER

NCT02314377 - Bevacizumab Therapy for Brain Arteriovenous Malformation | Biotech Hunter | Biotech Hunter